AF710B, a concomitant activator of M1 muscarinic and sigma-1 receptors: possible disease-modifying properties in McGill-R-Thy1-APP rats
Anavex Announces Two-Year Clinical Extension Study of ANAVEX 2-73 and Presents Phase 2a Dose-Response Analysis at AAT Conference
Sigma-1 Receptor Agonists Inhibit Oligodendrocyte Cytotoxicity Induced by Molecules Involved in Cell Damage in Multiple Sclerosis.
